CSCs Cancer Research Results
CSCs, Cancer Stem Cells: Click to Expand ⟱
Scientific Papers found: Click to Expand⟱
TumCG↓, Artemisinin (1, Figure 2) could suppress cell growth [16], reduce angiogenesis-related factors [17], and induce ferroptosis [18] in breast cancer cell lines
angioG↓,
Ferroptosis↑,
TumCP↑, Dihydroartemisinin (2, Figure 2) exhibited anticancer effects against breast cancer by suppressing cell proliferation [16], inhibiting angiogenesis [19], inducing autophagy [20] and pyroptosis [21], and targeting cancer stem cells (CSCs) [
TumAuto↑,
CSCs↑,
eff↑, Dihydroartemisinin is more potent than artemisinin, as the IC50 values at 24 h were lower on MCF-7 (129.1 μM versus 396.6 μM) and MDA-MB-231 (62.95 μM versus 336.63 μM)
YAP/TEAD↓, Additionally, dihydroartemisinin was proven to have the ability to reduce the expression of yes-associated protein 1 (YAP1), which has been commonly used as a prognostic marker in liver cancer.
TumCCA↑, induced G0/G1 cell cycle arrest and apoptosis by promoting oxygen species (ROS) accumulation.
ROS↑,
ChemoSen↑, The application of combination treatment using artemisinin and its derivatives with commonly used chemotherapy drugs, such as cisplatin, carboplatin, doxorubicin, temozolomide, etc., always exhibits significantly improved anticancer effects
N-cadherin↓, and inhibiting the proliferation, colony formation, and invasiveness of colon cancer cells by inhibiting NRP2, N-cadherin, and Vimentin expression
Vim↓,
MMP9↓, by decreasing the expression of HuR and matrix metalloproteinase (MMP)-9 proteins [24],
eff↑, Further investigations suggested that both dihydroartemisinin treatment and the loss of PRIM2 could lead to a decreased GSH level and induce cellular lipid ROS and mitochondrial MDA expression.
STAT3↓, Recently, artemisinin and its derivatives were reported to have potential as direct STAT3 inhibitors [98].
CD133↓, dihydroartemisinin treatment could significantly reduce the expression of CSC markers (CD133, CD44, Nanog, c-Myc, and OCT4) by downregulating Akt/mTOR pathway
CD44↓,
Nanog↓,
cMyc↓,
OCT4↓,
Akt↓,
mTOR↓,
CSCs↑, Salinomycin (1) exhibits a large spectrum of biological activities including the capacity to selectively eradicate cancer stem cells (CSC), making it and its derivatives promising candidates for the development of drug leads against CSC
| - |
in-vitro, |
BC, |
MCF-7 |
|
|
|
- |
in-vitro, |
BC, |
MDA-MB-231 |
|
|
|
eff↑, Herein, we improve the toxicity of salinomycin against cancer cells by telomerase inhibition BIBR1532 (BIBR), which binds to the active site of telomerase reverse transcriptase.
AntiCan↑, targeting telomerase improves anti-cancer effects of salinomycin.
CSCs↑, Until 2009, Weinberg group reported that salinomycin possessed anti-cancer effects, especially anti-cancer stem-like cell activities
Wnt↓, inhibition of the Wnt/β-catenin signaling pathway, induction differentiation, and overproduction of reactive oxygen species (ROS).
β-catenin/ZEB1↓,
Diff↑,
ROS↑,
toxicity↝, has been reported that salinomycin in high dose exhibits severe systemic adverse reactions in mammals, which hinders its application as a drug for human diseases.
selectivity↝, Therefore, it is urgent to find more effective methods for increasing salinomycin’s toxicity to cancer cells with little effects on normal cells.
eff↑, BIBR improves salinomycin’s toxicity partially through enhancing ROS generation.
AntiTum↑, salinomycin alone or in combination with FOLFOX exerts superior antitumor activity compared to FOLFOX therapy in a patient-derived mouse xenograft model of colorectal cancer
Apoptosis↑, Salinomycin induces apoptosis of human colorectal cancer cells, accompanied by accumulation of dysfunctional mitochondria and reactive oxygen species
mtDam↑,
ROS↑, Accumulation of dysfunctional mitochondria and increased production of reactive oxygen species upon salinomycin treatment
SOD1↓, These effects are associated with expressional down-regulation of superoxide dismutase-1 (SOD1) in response to salinomycin treatment.
ChemoSen↑, salinomycin alone or in combination with 5-fluorouracil and oxaliplatin exerts increased antitumoral activity compared to common chemotherapy.
CSCs↑, Anti-stem cell activity of salinomycin in TIC cultures
ALDH↓, Strikingly, exposure to 5-FU and oxaliplatin resulted in a more pronounced reduction of the ALDH1+ population compared to salinomycin treatment
TumCG↓, Salinomycin inhibits tumor growth in a patient-derived xenograft model
TumCP↓, Salinomycin inhibits proliferation, induces cell death and abolishes ATP production of human colorectal cancer cells
TumCD↑,
ATP↓,
Showing Research Papers: 1 to 4 of 4
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
Ferroptosis↑, 1, ROS↑, 3, SOD1↓, 1,
Mitochondria & Bioenergetics ⓘ
ATP↓, 1, mtDam↑, 1,
Core Metabolism/Glycolysis ⓘ
cMyc↓, 1,
Cell Death ⓘ
Akt↓, 1, Apoptosis↑, 1, Ferroptosis↑, 1, TumCD↑, 1, YAP/TEAD↓, 1,
Autophagy & Lysosomes ⓘ
TumAuto↑, 1,
Cell Cycle & Senescence ⓘ
TumCCA↑, 1,
Proliferation, Differentiation & Cell State ⓘ
ALDH↓, 1, CD133↓, 1, CD44↓, 1, CSCs↑, 4, Diff↑, 1, mTOR↓, 1, Nanog↓, 1, OCT4↓, 1, STAT3↓, 1, TumCG↓, 2, Wnt↓, 1,
Migration ⓘ
MMP9↓, 1, N-cadherin↓, 1, TumCP↓, 1, TumCP↑, 1, Vim↓, 1, β-catenin/ZEB1↓, 1,
Angiogenesis & Vasculature ⓘ
angioG↓, 1,
Drug Metabolism & Resistance ⓘ
ChemoSen↑, 2, eff↑, 4, selectivity↝, 1,
Functional Outcomes ⓘ
AntiCan↑, 1, AntiTum↑, 1, toxicity↝, 1,
Total Targets: 37
Pathway results for Effect on Normal Cells:
Total Targets: 0
Scientific Paper Hit Count for: CSCs, Cancer Stem Cells
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:795 State#:% Dir#:2
wNotes=on sortOrder:rid,rpid
Home Page